Lineage Cell Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
Lineage Cell Therapeutics, Inc. reported significant progress in its cell therapy pipeline and collaborations for 2025, alongside a substantial increase in net operating losses.
AMEX
Lineage Cell Therapeutics details its 2024 financial results and provides updates on its key programs, including OpRegen for geographic atrophy and OPC1 for spinal cord injuries.
AMEX
10-K: Lineage Cell Therapeutics Announces Separation and Consulting Agreement with Dr. Gary S. Hogge
Lineage Cell Therapeutics has entered into a separation, release, and consulting agreement with Dr. Gary S. Hogge, effective November 30, 2023, which includes separation benefits and a consulting period.